- Home
- MTAL vs SEPN Comparison
MTAL vs SEPN Comparison
Compare MTAL & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTAL
- SEPN
- Stock Information
- Founded
- MTAL 2021
- SEPN 2022
- Country
- MTAL Jersey
- SEPN United States
- Employees
- MTAL N/A
- SEPN N/A
- Industry
- MTAL Blank Checks
- SEPN
- Sector
- MTAL Finance
- SEPN
- Exchange
- MTAL Nasdaq
- SEPN NYSE
- Market Cap
- MTAL 690.2M
- SEPN 311.6M
- IPO Year
- MTAL 2021
- SEPN 2024
- Fundamental
- Price
- MTAL $9.61
- SEPN $6.69
- Analyst Decision
- MTAL Buy
- SEPN Buy
- Analyst Count
- MTAL 2
- SEPN 4
- Target Price
- MTAL $14.75
- SEPN $33.00
- AVG Volume (30 Days)
- MTAL 398.8K
- SEPN 181.2K
- Earning Date
- MTAL 04-29-2025
- SEPN 05-19-2025
- Dividend Yield
- MTAL N/A
- SEPN N/A
- EPS Growth
- MTAL N/A
- SEPN N/A
- EPS
- MTAL N/A
- SEPN N/A
- Revenue
- MTAL $340,736,000.00
- SEPN $1,075,000.00
- Revenue This Year
- MTAL $21.74
- SEPN N/A
- Revenue Next Year
- MTAL $19.03
- SEPN N/A
- P/E Ratio
- MTAL N/A
- SEPN N/A
- Revenue Growth
- MTAL 114.30
- SEPN 611.92
- 52 Week Low
- MTAL $7.69
- SEPN $4.17
- 52 Week High
- MTAL $15.26
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- MTAL 56.65
- SEPN N/A
- Support Level
- MTAL $8.61
- SEPN N/A
- Resistance Level
- MTAL $9.66
- SEPN N/A
- Average True Range (ATR)
- MTAL 0.37
- SEPN 0.00
- MACD
- MTAL 0.10
- SEPN 0.00
- Stochastic Oscillator
- MTAL 90.45
- SEPN 0.00
About MTAL Metals Acquisition Limited
MAC Copper Ltd is a company focused on operating and acquiring metals and mining businesses in high-quality, stable jurisdictions that are critical in the electrification and decarbonization of the world-wide economy.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.